These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27588191)

  • 1. Comparison of the efficacy of icotinib in patients with non-small-cell lung cancer according to the type of epidermal growth factor receptor mutation.
    Xue ZX; Wen WX; Zhuang Y; Hua ZJ; Xia YN
    Mol Clin Oncol; 2016 Sep; 5(3):265-268. PubMed ID: 27588191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
    Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q
    Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
    World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
    Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
    J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
    Igawa S; Kasajima M; Ishihara M; Kimura M; Hiyoshi Y; Asakuma M; Otani S; Katono K; Sasaki J; Masuda N
    Oncology; 2014; 87(4):215-23. PubMed ID: 25034225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
    Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
    Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis.
    Wang L; Li Y; Li L; Wu Z; Yang D; Ma H; Wang D
    Onco Targets Ther; 2018; 11():2345-2353. PubMed ID: 29731642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable response to icotinib in a lung cancer patient with a special mutation at exon 19 of epidermal growth factor receptor.
    Zheng H; Wang Q; Shi H; Zhang H; Hu F; Li B
    Thorac Cancer; 2014 Jul; 5(4):358-61. PubMed ID: 26767025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
    Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
    Choi YW; Choi JH
    Korean J Intern Med; 2017 May; 32(3):422-428. PubMed ID: 28352061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of
    Igawa S; Ono T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Yokoba M; Katagiri M; Naoki K
    Cancer Manag Res; 2019; 11():4883-4892. PubMed ID: 31213907
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced non-small cell lung cancer.
    Ni J; Liu DY; Hu B; Li C; Jiang J; Wang HP; Zhang L
    Cancer; 2015 Sep; 121 Suppl 17():3146-56. PubMed ID: 26331821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: Systematic review and meta analysis.
    Liu Y; Ren Z; Wang J; Zhang S
    Thorac Cancer; 2016 Jul; 7(4):406-14. PubMed ID: 27385982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer.
    Zhang Y; Chen G; Chen X; Fang W; Gao F; Yang Y; Zhao Y; Ma Y; Hong S; Zhang Z; Miao S; Wu M; Huang X; Luo Y; Zhou C; Gong R; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
    J Cancer; 2017; 8(10):1865-1871. PubMed ID: 28819384
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
    Li X; Qin N; Wang J; Yang X; Zhang X; Lv J; Wu Y; Zhang H; Nong J; Zhang Q; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):734-9. PubMed ID: 26706949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
    BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.